What Is Enzalutamide 40 mg?
Enzalutamide 40 mg is an oral hormonal anticancer medicine containing enzalutamide, a potent androgen receptor signaling inhibitor.
It is used to treat certain forms of prostate cancer.
Prostate cancer develops when abnormal cells in the prostate gland grow and multiply uncontrollably.
Many prostate cancer cells depend on androgens, such as testosterone and dihydrotestosterone, to support their growth.
These hormones interact with androgen receptors inside prostate cancer cells.
When activated, androgen receptors stimulate biological processes that promote cancer cell growth and survival.
Enzalutamide works by blocking androgen receptor signaling.
Unlike medicines that primarily reduce testosterone production, enzalutamide directly interferes with the action of androgens at their receptors.
This helps reduce androgen-driven cancer cell activity.
Enzalutamide is used in several prostate cancer settings, including metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer and certain patients with high-risk biochemical recurrence.
The exact treatment regimen depends on the stage of disease, previous treatment, hormone status and applicable prescribing guidelines.
Enzalutamide may be used alongside androgen deprivation therapy (ADT).
In certain approved high-risk biochemical recurrence settings, it may be used with or without a gonadotropin-releasing hormone (GnRH) analog.
Important: Enzalutamide is not conventional cytotoxic chemotherapy. It is a targeted hormonal anticancer treatment that blocks androgen receptor signaling.
How Does Enzalutamide 40 mg Work?
1. Blocks Androgen Receptors
Enzalutamide competitively inhibits androgen binding to androgen receptors.
2. Prevents Androgen Receptor Activation
By blocking receptor activation, it reduces androgen-driven signaling within prostate cancer cells.
3. Inhibits Receptor Nuclear Translocation
Enzalutamide interferes with the movement of activated androgen receptors into the cell nucleus.
4. Reduces Androgen Receptor Binding to DNA
It inhibits androgen receptor interactions with DNA that regulate cancer-related gene expression.
5. Suppresses Androgen-Dependent Gene Transcription
Enzalutamide reduces the activation of genes involved in androgen-driven prostate cancer growth.
6. Slows Cancer Cell Proliferation
By interfering with androgen signaling, it can slow the growth of susceptible prostate cancer cells.
7. Supports Disease Progression Control
Enzalutamide can delay disease progression in selected prostate cancer populations.
8. Provides Systemic Hormonal Anticancer Activity
Because it is administered orally and absorbed systemically, enzalutamide acts throughout the body.
Important: Treatment response varies according to disease stage, previous therapies, tumor biology and individual patient factors.
Uses of Enzalutamide 40 mg
1. Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Enzalutamide is used for patients with metastatic prostate cancer that continues to progress despite castrate levels of testosterone.
It may be prescribed before or after certain other systemic treatments, depending on the clinical situation.
2. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Enzalutamide is used in selected patients whose prostate cancer progresses despite castrate testosterone levels but who have no detectable distant metastases on conventional imaging.
3. Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Enzalutamide may be used with appropriate androgen deprivation therapy in patients with metastatic prostate cancer that remains sensitive to testosterone suppression.
4. High-Risk Biochemical Recurrent Prostate Cancer
Enzalutamide is approved in certain jurisdictions for patients with non-metastatic castration-sensitive prostate cancer who have biochemical recurrence and are at high risk of metastasis.
5. Androgen Receptor Signaling Inhibition
Enzalutamide blocks androgen receptor activity involved in prostate cancer growth.
6. Prostate Cancer Progression Management
It may help delay radiographic or clinical progression in appropriately selected patients.
7. Systemic Hormonal Therapy
Enzalutamide may form part of a comprehensive prostate cancer treatment plan.
8. Treatment After Previous Prostate Cancer Therapy
It may be prescribed following earlier treatment, depending on disease characteristics and previous medicines.
Important: Enzalutamide is not an approved treatment for every type of cancer. It should not be promoted as a general cancer cure or a substitute for specialist assessment.
How to Take Enzalutamide 40 mg
Enzalutamide must be taken exactly as prescribed.
General Administration Instructions
- Confirm the prescribed strength and dosage.
- Take the medicine at approximately the same time each day.
- Swallow capsules whole with water.
- Do not crush, chew, dissolve or open capsules.
- Take the medicine with or without food.
- Follow the prescribed androgen deprivation treatment plan when applicable.
- Do not change the dose independently.
- Attend scheduled oncology appointments.
- Report significant side effects promptly.
- Inform the healthcare team about all medicines and supplements.
Dosage Information
| Dosage Detail | General Guidance |
|---|---|
| Strength | 40 mg |
| Standard Adult Dose | 160 mg Once Daily |
| Number of 40 mg Capsules | Four Capsules |
| Route | Oral |
| Administration | With or Without Food |
| Frequency | Once Daily |
| Dose Adjustment | Based on Adverse Effects and Drug Interactions |
| Treatment Duration | Determined by Oncology Specialist |
| Missed Dose | Follow Product Instructions |
| Monitoring | Clinical Response, PSA, Blood Pressure and Adverse Effects |
Important: The standard 160 mg dose is not suitable for every clinical situation. Dose modifications may be required.
Can Enzalutamide Be Taken With Food?
Yes. Enzalutamide can be taken with or without food.
Can Enzalutamide Be Taken Daily?
Yes. It is generally prescribed once daily.
Can Enzalutamide Be Used With Hormone Therapy?
Yes. Enzalutamide is commonly used with ongoing androgen deprivation therapy.
For certain high-risk biochemical recurrence settings, the approved regimen may differ.
Can Enzalutamide Be Used Without Chemotherapy?
Yes. Enzalutamide is a hormonal targeted therapy and may be prescribed independently of conventional cytotoxic chemotherapy.
What If a Dose Is Missed?
If a dose is missed, follow the product instructions.
For standard U.S. labeling, a missed dose may be taken when remembered on the same day.
If an entire day is missed, resume the usual schedule the following day.
Do not take more than the prescribed daily dose to compensate.
What If Too Much Enzalutamide Is Taken?
Seek medical attention promptly.
Excessive dosing may increase the risk of serious adverse effects, including seizures.
How Long Does Enzalutamide 40 mg Take to Work?
Enzalutamide begins interfering with androgen receptor signaling after administration.
However, clinical response is assessed over time.
During the First Several Weeks
The medicine begins exerting its antiandrogen effects.
During Continued Treatment
The oncology team may assess prostate-specific antigen (PSA) levels, symptoms and treatment tolerability.
During Scheduled Imaging
Imaging studies may be used to evaluate disease progression or treatment response.
During Long-Term Treatment
Therapy may continue while it remains clinically appropriate and adverse effects are manageable.
Important: PSA changes alone do not provide a complete assessment of treatment effectiveness.
Common Side Effects
Possible side effects include:
- Fatigue
- Weakness
- Hot Flashes
- Joint Pain
- Muscle Pain
- Back Pain
- Headache
- Dizziness
- Reduced Appetite
- Constipation
- Diarrhea
- High Blood Pressure
- Falls
- Weight Changes
- Sleep Disturbances
- Peripheral Swelling
- Cognitive or Concentration Difficulties
The frequency and severity of adverse effects vary between patients.
Serious Side Effects
Seek urgent medical attention for:
- Seizures
- Sudden loss of consciousness
- Severe confusion
- Chest pain
- Sudden shortness of breath
- Stroke-like symptoms
- Severe allergic reactions
- Swelling of the face, lips or tongue
- Severe headache with visual disturbances
- Serious falls or fractures
- Severe skin reactions
Important Serious Risks
1. Seizures
Enzalutamide can increase the risk of seizures.
Patients with seizure risk factors require careful assessment.
2. Posterior Reversible Encephalopathy Syndrome (PRES)
A rare neurological condition may cause seizures, headache, confusion and visual disturbances.
3. Ischemic Heart Disease
Serious ischemic cardiac events have been reported.
4. Falls and Fractures
Enzalutamide is associated with increased risks of falls and fractures.
5. Hypertension
Blood pressure may increase during treatment.
6. Hypersensitivity Reactions
Serious allergic reactions, including angioedema, may occur.
7. Severe Cutaneous Adverse Reactions
Rare serious skin reactions, including Stevens–Johnson syndrome, have been reported.
8. Cognitive and Neurological Effects
Some patients experience dizziness, memory problems or difficulty concentrating.
Contraindications & Precautions
1. Seizure Risk
Patients with a history of seizures or conditions that lower seizure threshold should inform their oncologist.
2. Neurological Disorders
Patients with significant neurological conditions require careful assessment.
3. Posterior Reversible Encephalopathy Syndrome
Severe headache, seizures, confusion or visual disturbances require urgent evaluation.
4. Cardiovascular Disease
Patients with ischemic heart disease or other significant cardiovascular conditions should be monitored.
5. Hypertension
Blood pressure should be assessed and managed during treatment.
6. Falls and Fractures
Patients with mobility limitations, osteoporosis or fracture risk factors may require additional precautions.
7. Bone Health
Long-term prostate cancer hormonal treatment may affect bone health.
8. Drug Interactions
Enzalutamide can affect the metabolism of many other medicines.
It is a strong inducer of CYP3A4 and can induce CYP2C9 and CYP2C19.
Examples of medicines requiring interaction review include:
- Warfarin
- Certain Anticoagulants
- Some Antiepileptic Medicines
- Certain Antifungal Medicines
- Some Cardiovascular Medicines
- Selected Pain Medicines
- Other Anticancer Medicines
9. Strong CYP2C8 Inhibitors
Strong CYP2C8 inhibitors, such as gemfibrozil, may increase enzalutamide exposure and require dose modification.
10. Strong CYP3A4 Inducers
Strong CYP3A4 inducers may reduce enzalutamide exposure and should generally be avoided when possible.
11. Liver Disease
Patients with significant liver disease should inform their healthcare professional.
12. Kidney Disease
Patients with severe kidney impairment require individualized assessment because clinical data are limited.
13. Pregnancy Exposure
Enzalutamide can cause fetal harm.
It is not indicated for use in women.
14. Contraception
Male patients with partners who can become pregnant should use effective contraception during treatment and for three months after the final dose.
15. Fertility
Enzalutamide may impair male fertility.
16. Driving and Machinery
Patients experiencing dizziness, fatigue, seizures or cognitive changes should avoid driving and hazardous activities.
17. Treatment Adherence
Consistent administration is important.
Patients should not stop treatment independently.
18. Medical Monitoring
Healthcare professionals may monitor:
- Prostate-Specific Antigen (PSA)
- Clinical Disease Progression
- Imaging Results
- Blood Pressure
- Fatigue
- Weakness
- Falls
- Fracture Risk
- Bone Health
- Cardiovascular Symptoms
- Neurological Symptoms
- Seizure Risk
- Cognitive Changes
- Medication Interactions
- Treatment Adherence
- Adverse Effects
- Dose Tolerability
- Overall Performance Status
Potential Therapeutic Advantages
- Androgen Receptor Inhibition.
- Targeted Hormonal Anticancer Therapy.
- Prostate Cancer Management.
- Metastatic Castration-Resistant Prostate Cancer Treatment.
- Non-Metastatic Castration-Resistant Prostate Cancer Treatment.
- Metastatic Castration-Sensitive Prostate Cancer Treatment.
- High-Risk Biochemical Recurrence Management.
- Androgen Signaling Suppression.
- Oral Administration.
- Once-Daily Standard Regimen.
- Systemic Anticancer Activity.
- Potential Disease Progression Delay.
- Established Prostate Cancer Treatment.
- Individualized Treatment Planning.
- Specialist-Supervised Therapy.
Disadvantages / Limitations
- Seizure Risk.
- Fatigue.
- Weakness.
- Hot Flashes.
- Hypertension.
- Falls.
- Fracture Risk.
- Joint Pain.
- Muscle Pain.
- Dizziness.
- Cognitive Changes.
- Cardiovascular Complications.
- Significant Drug Interactions.
- Potential Fertility Effects.
- Requires Regular Monitoring.
- Limited to Selected Prostate Cancer Indications.
- Does Not Guarantee Cancer Cure.
- Requires Oncology Supervision.
Important Notes
Generic Name: Enzalutamide.
Strength: 40 mg.
Drug Class: Androgen Receptor Inhibitor.
Therapeutic Category: Hormonal Anticancer Therapy.
Primary Indication: Selected Prostate Cancer Settings.
Mechanism of Action: Androgen Receptor Signaling Inhibition.
Route: Oral.
Standard Adult Dose: 160 mg Once Daily.
40 mg Capsules per Standard Dose: Four.
Administration: With or Without Food.
Major Neurological Risk: Seizures.
Cardiovascular Precaution: Ischemic Heart Disease.
Fall and Fracture Risk: Increased.
Drug Interaction Potential: Significant.
Medical Supervision: Oncology Specialist Required.
Storage: Follow Original Product Labeling.
Frequently Asked Questions
1. What is Enzalutamide 40 mg used for?
It is used for selected forms of prostate cancer, including metastatic and non-metastatic disease.
2. Is Enzalutamide a chemotherapy medicine?
It is a targeted hormonal anticancer medicine rather than conventional cytotoxic chemotherapy.
3. How does Enzalutamide work?
It blocks androgen receptor signaling involved in prostate cancer growth.
4. Is Enzalutamide used for metastatic prostate cancer?
Yes. It is used in selected patients with metastatic castration-resistant and metastatic castration-sensitive prostate cancer.
5. Is Enzalutamide used for non-metastatic prostate cancer?
Yes. It is approved for certain non-metastatic castration-resistant and high-risk biochemical recurrent prostate cancer settings.
6. What is the standard Enzalutamide dose?
The standard adult dose is 160 mg once daily.
































































